Compare JBGS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBGS | EYPT |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 967.4M |
| IPO Year | 2017 | 2005 |
| Metric | JBGS | EYPT |
|---|---|---|
| Price | $18.04 | $14.25 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $16.50 | ★ $29.60 |
| AVG Volume (30 Days) | 722.3K | ★ 1.3M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $501,226,000.00 | $42,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.28 | $3.91 |
| 52 Week High | $24.30 | $14.96 |
| Indicator | JBGS | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 40.29 | 60.29 |
| Support Level | $17.36 | $13.43 |
| Resistance Level | $18.69 | $14.96 |
| Average True Range (ATR) | 0.58 | 0.85 |
| MACD | 0.14 | 0.23 |
| Stochastic Oscillator | 60.69 | 81.25 |
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.